How Will the Market React to Portage Biotech Inc (PRTG) Stock Getting a Bullish Rating

Overall market sentiment has been high on Portage Biotech Inc (PRTG) stock lately. PRTG receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Portage Biotech Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on PRTG!

See Full PRTG Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With PRTG Stock Today?

Portage Biotech Inc (PRTG) stock is lower by -2.36% while the S&P 500 has risen 0.32% as of 1:12 PM on Thursday, Jul 27. PRTG has fallen -$0.07 from the previous closing price of $3.06 on volume of 39,332 shares. Over the past year the S&P 500 has risen 16.84% while PRTG has fallen -70.04%. PRTG lost -$1.17 per share in the over the last 12 months. To screen for more stocks like Portage Biotech Inc click here.

More About Portage Biotech Inc

Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others. Click Here to get the full Stock Report for Portage Biotech Inc stock.